Article ; Online: Breaking Bad
2021 Volume 16, Issue 10, Page(s) 1523–1536
Abstract: The COVID-19 pandemic has brought renewed attention to the topic of challenging drug patents in the interest of public health. Pharmaceutical companies have already begun to patent existing medicines for the treatment and prevention of SARS-CoV-2, ... ...
Abstract | The COVID-19 pandemic has brought renewed attention to the topic of challenging drug patents in the interest of public health. Pharmaceutical companies have already begun to patent existing medicines for the treatment and prevention of SARS-CoV-2, affording them exclusive manufacturing rights over vital medicines. Advocates have raised concerns regarding the pricing of COVID-19 drugs, as well as patent monopolies on the manufacture of COVID-19 treatments. The HIV/AIDS pandemic provides a useful lens through which we can analyse existing pathways for challenging pharmaceutical patents in the context of global pandemic. In this article, we review three legal pathways for overriding and seizing patents on medicines by describing cases in which they were employed to make antiretroviral drugs more accessible to people living with HIV. Last, we highlight the weaknesses inherent in these pathways and offer advocacy and policy suggestions for how to strengthen these pathways to improve access to COVID-19 treatments as they become available in the United States and globally. |
---|---|
MeSH term(s) | Acquired Immunodeficiency Syndrome ; Drug Industry ; Humans ; Pandemics/prevention & control ; SARS-CoV-2 ; United States ; COVID-19 Drug Treatment |
Language | English |
Publishing date | 2021-05-08 |
Publishing country | England |
Document type | Journal Article ; Research Support, N.I.H., Extramural ; Review |
ZDB-ID | 2234129-8 |
ISSN | 1744-1706 ; 1744-1706 |
ISSN (online) | 1744-1706 |
ISSN | 1744-1706 |
DOI | 10.1080/17441692.2021.1924223 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.